Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,752 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Major Depressive Disorders Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate ), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Carson, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 23, 2026, 9:22 AM EDT
Suspended Phase 2 Interventional

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

NCT06705478
View directory record Official record
Conditions
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
Interventions
Pramipexole ER, Escitalopram
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Of GW679769 In Major Depressive Disorder

NCT00102492
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

The Effects of Estrogen Withdrawal on Mood Symptoms in Women

NCT00060736
View directory record Official record
Conditions
Perimenopausal Depression, Post Menopausal, Healthy, Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
45 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 23, 2026, 9:22 AM EDT
Not listed No phase listed Observational

Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression

NCT01768052
View directory record Official record
Conditions
Major Depression
Interventions
functional Near Infrared Spectroscopy
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 23, 2026, 9:22 AM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Appalachian Mind Health Initiative

NCT04120285
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
remote internet-based cognitive behavior therapy (eCBT)
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Louisville, Kentucky • Cedar Grove, West Virginia • Glenville, West Virginia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

Exploring a Potential Blood Test to Diagnose Major Depressive Disorder

NCT00705185
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Farmington, Connecticut • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2010 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement

NCT03242213
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mobile App
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01361555
View directory record Official record
Conditions
Depression
Interventions
Placebo matching with BMS-820836, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
94
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder

NCT00039715
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Results available

Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study

NCT01162382
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder

NCT00813735
View directory record Official record
Conditions
Insomnia
Interventions
Eszopiclone, Placebo, Escitalopram
Drug
Lead sponsor
Lehigh Center for Clinical Research
Other
Eligibility
65 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional

Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder

NCT00143091
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
CP-316,311, Placebo, Sertraline
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Bellevue, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

NCT06419608
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
62
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Depression

NCT00050700
View directory record Official record
Conditions
Depression, Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Phase 4 Interventional

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

NCT03537547
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Depressive Episode, Depression, Unipolar
Interventions
GeneSight Psychotropic test, FDA-approved antidepressant or antipsychotic treatment
Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Ketamine for Depression and Suicide Risk

NCT02094898
View directory record Official record
Conditions
Depression, Suicide
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain GABA Levels and Treatment Response in Major Depressive Disorder

NCT00464711
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD

NCT06979544
View directory record Official record
Conditions
Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression
Interventions
LPCN 1154A, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
18
States / cities
Anahiem, California • Canoga Park, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Active, not recruiting Phase 4 Interventional

Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study

NCT05950711
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Combination use of MBCT and IV Ketamine
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional

A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety

NCT02948036
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mobile-device, plasticity-based adaptive cognitive treatment
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Genotype on LY2216684

NCT01460381
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Quinidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

NCT00880399
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
orvepitant, placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Arcadia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 23, 2026, 9:22 AM EDT